Benjamin Graham Detailed Fundamental Analysis

Validea's Benjamin Graham-based Value Investor model assigned INTUITIVE SURGICAL INC (ISRG) its highest rating at 71%, screening for deep value characteristics such as low P/B and P/E ratios, low debt, and strong long-term EPS growth. While ISRG passed criteria for sales, debt, and long-term EPS, it notably failed on P/E and Price/Book ratios, leading to a score below the 80% threshold typically indicating 'some interest' for this deep value strategy.

Analysis

Intuitive Surgical Inc. (ISRG) receives a mixed assessment from Validea's Benjamin Graham-based value investing model, scoring 71%, which is below the 80% threshold that typically indicates strategic interest. The analysis highlights a clear dichotomy in the company's profile: ISRG exhibits strong fundamental health, passing criteria for its sales, current ratio, low long-term debt relative to net current assets, and solid long-term EPS growth. However, it fails on the two core valuation metrics central to the Graham methodology, namely its high Price-to-Earnings (P/E) and Price-to-Book (P/B) ratios. This outcome underscores the conflict between ISRG's classification as a large-cap growth stock, which commands premium valuations, and the stringent requirements of a deep value investment strategy.

Key Decisions for Investors

• Strict value investors should note that ISRG fails to meet key valuation criteria, suggesting it may be too expensive for a classic deep value portfolio despite its strong operational fundamentals.
• Growth-oriented investors can interpret the report as a confirmation of ISRG's robust financial health and growth trajectory, as evidenced by its passing marks on EPS growth, sales, and balance sheet stability.
• Investors with a hybrid approach should weigh the company's premium valuation against its demonstrated fundamental strengths, recognizing that future returns are highly dependent on sustaining growth to justify the current stock price.